Emergent BioSolutions Inc. - Common Stock (EBS) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
EBS on NYSE
Shares outstanding
54,486,781
Price per share
$12.36
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
41,696,731
Total reported value
$352,475,779
% of total 13F portfolios
0%
Share change
+2,028,888
Value change
+$19,667,117
Number of holders
167
Price from insider filings
$12.36
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Emergent BioSolutions Inc. - Common Stock (EBS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.3% $23,228,804 3,977,535 BlackRock, Inc. 30 Jun 2025

As of 30 Sep 2025, 167 institutional investors reported holding 41,696,731 shares of Emergent BioSolutions Inc. - Common Stock (EBS). This represents 77% of the company’s total 54,486,781 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Emergent BioSolutions Inc. - Common Stock (EBS) together control 61% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 7.8% 4,263,123 -2.2% 0% $37,600,745
OAK HILL ADVISORS LP 6.6% 3,613,338 0% 3.5% $16,566,289
VANGUARD GROUP INC 6.5% 3,540,670 -1.2% 0% $31,228,709
STATE STREET CORP 4.5% 2,445,759 +40% 0% $21,571,594
AMERICAN CENTURY COMPANIES INC 4.4% 2,382,378 +3.9% 0.01% $21,012,574
DIMENSIONAL FUND ADVISORS LP 3.9% 2,140,340 +16% 0% $18,878,293
PALISADE CAPITAL MANAGEMENT, LP 2.6% 1,426,019 +30% 0.34% $12,577,488
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 2.5% 1,381,750 +25% 0% $12,187,035
GEODE CAPITAL MANAGEMENT, LLC 2.3% 1,278,693 -0.02% 0% $11,280,337
ACADIAN ASSET MANAGEMENT LLC 2.2% 1,177,661 +21% 0.02% $10,383,000
Connor, Clark & Lunn Investment Management Ltd. 2.1% 1,132,305 +15% 0.03% $9,986,930
MARSHALL WACE, LLP 1.7% 912,388 -10% 0.01% $8,047,261
LSV ASSET MANAGEMENT 1.6% 864,500 +6% 0.02% $7,625,000
Prescott Group Capital Management, L.L.C. 1.4% 772,771 0% 0.72% $6,815,840
NORTHERN TRUST CORP 1.2% 637,832 +43% 0% $5,625,679
GOLDMAN SACHS GROUP INC 1.1% 620,977 +7.2% 0% $5,477,017
AQR CAPITAL MANAGEMENT LLC 1.1% 586,246 0% $5,170,690
Pacer Advisors, Inc. 0.98% 536,655 -3.6% 0.01% $4,733,297
MORGAN STANLEY 0.97% 528,875 -28% 0% $4,664,686
Trexquant Investment LP 0.97% 526,288 -4.6% 0.05% $4,641,860
NEW YORK STATE COMMON RETIREMENT FUND 0.96% 522,004 +33% 0.01% $4,604,075
RENAISSANCE TECHNOLOGIES LLC 0.95% 518,247 -25% 0.01% $4,570,939
Jain Global LLC 0.93% 508,707 0.06% $4,486,796
UBS Group AG 0.81% 439,375 -9.2% 0% $3,875,288
FEDERATED HERMES, INC. 0.74% 401,258 +44% 0.01% $3,539,096

Institutional Holders of Emergent BioSolutions Inc. - Common Stock (EBS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 389,880 $4,807,906 +$1,046,852 $12.36 17
2025 Q3 41,696,731 $352,475,779 +$19,667,117 $8.82 167
2025 Q2 36,048,259 $229,963,501 +$8,627,432 $6.38 159
2025 Q1 36,190,861 $175,869,890 +$2,175,906 $4.86 158
2024 Q4 34,725,918 $331,954,109 +$28,059,002 $9.56 155
2024 Q3 31,685,912 $264,526,500 +$30,958,198 $8.35 138
2024 Q2 30,424,097 $207,508,612 -$26,561,530 $6.82 138
2024 Q1 35,867,681 $90,688,369 -$11,961,854 $2.53 116
2023 Q4 44,417 $106,601 +$58,447 $2.40 2
2023 Q3 41,326,487 $140,783,685 -$26,266,289 $3.40 158
2023 Q2 45,670,500 $335,708,462 +$1,389,912 $7.35 176
2023 Q1 44,931,048 $465,320,127 -$16,658,400 $10.36 185
2022 Q4 46,214,925 $545,784,244 +$43,474,772 $11.81 189
2022 Q3 40,056,938 $840,738,058 -$34,784,451 $20.99 187
2022 Q2 41,102,900 $1,262,396,008 -$31,127,768 $31.04 213
2022 Q1 41,689,607 $1,712,020,816 -$3,007,977 $41.06 228
2021 Q4 42,438,927 $1,845,959,029 -$78,943,579 $43.47 237
2021 Q3 44,329,165 $2,219,807,625 -$14,735,557 $50.07 268
2021 Q2 44,030,647 $2,772,469,828 -$90,897,949 $62.99 283
2021 Q1 44,538,698 $4,132,289,205 +$74,186,002 $92.91 334
2020 Q4 41,035,626 $3,677,846,354 +$69,030,368 $89.60 346
2020 Q3 39,680,151 $4,101,722,379 -$171,595,900 $103.33 350
2020 Q2 53,110,910 $4,155,188,937 -$1,228,124 $79.08 292
2020 Q1 43,626,472 $2,523,826,152 +$8,001,400 $57.86 251
2019 Q4 44,586,943 $2,405,632,656 -$6,236,173 $53.95 229
2019 Q3 44,141,923 $2,307,031,757 -$7,482,544 $52.28 235
2019 Q2 44,347,714 $2,142,008,219 +$144,554,186 $48.31 224
2019 Q1 44,244,540 $2,235,333,390 +$84,261,049 $50.52 264
2018 Q4 42,439,504 $2,514,950,934 +$49,771,840 $59.28 291
2018 Q3 41,468,568 $2,729,128,193 +$23,298,675 $65.83 265
2018 Q2 41,488,613 $2,095,115,218 +$58,157,144 $50.49 254
2018 Q1 40,880,255 $2,146,326,638 +$60,996,570 $52.65 268
2017 Q4 38,926,007 $1,809,985,770 +$151,424,618 $46.47 232
2017 Q3 36,901,762 $1,492,872,969 +$60,938,052 $40.45 193
2017 Q2 35,580,325 $1,198,097,570 +$5,031,601 $33.91 179
2017 Q1 34,590,441 $1,004,599,223 +$86,418,619 $29.04 172
2016 Q4 34,763,794 $1,140,902,889 -$15,838,416 $32.84 202
2016 Q3 35,869,477 $1,129,692,915 -$1,397,280 $31.53 197
2016 Q2 35,468,783 $998,475,072 +$87,136,097 $28.12 213
2016 Q1 32,834,153 $1,194,106,935 +$24,145,321 $36.35 204
2015 Q4 32,254,623 $1,290,343,471 +$25,433,356 $40.01 199
2015 Q3 32,001,168 $911,746,058 +$33,467,439 $28.49 189
2015 Q2 30,483,833 $1,004,416,909 +$19,758,700 $32.95 178
2015 Q1 30,344,222 $872,697,011 +$37,398,136 $28.76 167
2014 Q4 28,864,718 $786,083,069 -$143,518 $27.23 159
2014 Q3 28,825,281 $614,994,160 -$34,839 $21.31 158
2014 Q2 28,678,530 $644,111,994 +$10,764,943 $22.46 155
2014 Q1 28,561,210 $721,795,209 +$91,025,805 $25.27 161